{"id":179964,"name":"HORIZON THERAPEUTICS (F/K/A) HORIZON PHARMA USA INC","slug":"horizon-therapeutics-fka-horizon-pharma-usa-inc","state":"IL","country":"United States of America","description":"Biopharmaceutical company","totalSpending":1430000,"filings":25,"yearlySpending":[{"year":2018,"income":330000},{"year":2019,"income":240000},{"year":2020,"income":220000},{"year":2021,"income":180000},{"year":2022,"income":160000},{"year":2023,"income":300000}],"issues":[{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"PHA","display":"Pharmacy"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORA"],"lobbyists":["ANDREW NEHRING","JACOB DANIELS","CHRISTIAN BOURGE","BRYCE DUSTMAN","ROBERT STRYK"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","White House Office","Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)","Natl Economic Council (NEC)","Natl Institutes of Health (NIH)","Office of the Vice President of the United States"],"sampleDescriptions":["Tax Reform, generally; HR 1,  An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (Tax Cuts and Jobs Act).","340B Refprm; drug pricing and general pharmaceutical issues; 340B definition of \"Patient;\"\nExecutive order on Drug Pricing","340B Reform; drug pricing and general pharmaceutical issues; 340B definition of \"Patient;\"\nExecutive order on Drug Pricing;  Administration Prescription Drug Policy.","340B Reform; drug pricing and general pharmaceutical issues; 340B definition of \"Patient;\"\nExecutive order on Drug Pricing;  Administration Prescription Drug Policy.","340B Reform; drug pricing and general pharmaceutical issues; 340B definition of \"Patient;\"\nExecutive order on Drug Pricing;  Administration Prescription Drug Policy."]}